Acadia Pharmaceuticals | ACAD - Equity Capital And Reserves


Acadia Pharmaceuticals reported $1.31B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
Eisai JPY 906.56B 7.57B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Moderna USD 6.76B 647M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Prothena USD 286.89M 25.72M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026